U.S. Metals and Mining Stock News

Pentair stock snapshot and recent performance Pentair (PNR) has been on many watchlists after a period of weaker share performance, with the stock showing negative returns over the past week, month, and past 3 months despite a positive 1 year total return. See our latest analysis for Pentair. At a share price of $92.17, Pentair’s recent 1 day, 7 day and 90 day share price returns have been negative, while its 1 year and 3 year total shareholder returns remain positive, suggesting shorter term...

Knight-Swift Transportation Holdings (KNX) is back in focus after recent trading left the stock with mixed short term moves, including a 1-day decline and a negative month, alongside a positive past 3 months. See our latest analysis for Knight-Swift Transportation Holdings. At a share price of $56.87, Knight-Swift’s recent 1-day and 7-day share price declines sit against an 11.49% 3-month share price return and a 22.54% 1-year total shareholder return. This suggests longer term momentum has...

The recent US jobs report, which showed an unexpected decline in employment and roughly 30,000 restaurant and bar jobs lost, has pressured sentiment around Darden Restaurants (DRI) as investors reassess consumer discretionary spending. See our latest analysis for Darden Restaurants. The share price reaction to the weak jobs data comes after a 12.95% 90 day share price return that has now cooled, leaving Darden at US$203.18 with 7.51% 1 year total shareholder return and a much stronger 55.63%...

Zymeworks Inc. has released its fourth quarter and full-year 2025 results, reporting a net loss of US$41.21 million for the quarter and US$81.13 million for the year, alongside basic and diluted loss per share from continuing operations of US$0.55 for the quarter and US$1.08 for the year. On the same day, the company also filed a US$79.29 million shelf registration for 3,404,536 common shares under an ESOP-related offering, highlighting both ongoing capital needs and an increased emphasis on...

Apellis Pharmaceuticals, Inc. announced that Mikael Dolsten, M.D., Ph.D., former Pfizer chief scientific officer, joined its board of directors on March 1, 2026, adding decades of pharmaceutical R&D leadership to the company. Dolsten’s track record overseeing the regulatory approval of more than 36 medicines and vaccines may influence how investors assess Apellis’s ability to advance and commercialize its pipeline. Next, we’ll examine how Dolsten’s board appointment could interact with...

In recent months, PC Connection, Inc. reported flat year-on-year Q4 revenue that fell short of analyst expectations amid sector-wide hardware and supply chain headwinds. At the same time, the company raised its quarterly dividend and saw a sharp drop in short interest, developments that may signal improving confidence from both management and investors despite operational challenges. Next, we’ll examine how the dividend increase shapes PC Connection’s investment narrative around cash...

Why today’s sector jitters hit Walker & Dunlop Investor concern around private credit exposure, following Western Alliance Bancorporation’s loan write off, fed into fresh volatility for Walker & Dunlop (WD), even though the news is focused on sector risk rather than company specific developments. See our latest analysis for Walker & Dunlop. The 1 day share price return of 4.59% decline at a last close of $48.19 comes after a 7 day share price return of 4.74%, but a 30 day share price return...

In February 2026, Vaxcyte, Inc. reported a full-year 2025 net loss of US$766.63 million and completed a US$408.1 million follow-on equity offering, while also filing an additional US$500 million at-the-market program and a US$473.86 million shelf registration related to employee stock plans. These moves collectively highlight Vaxcyte’s reliance on equity financing to support its vaccine pipeline while absorbing widening losses, a pattern that can influence how investors assess funding risk...

In February 2026, Agilent Technologies reported first-quarter 2026 sales of US$1,798 million, with net income of US$305 million, and raised full-year 2026 revenue guidance to a range of US$7.30 billion to US$7.50 billion while issuing new second-quarter revenue guidance of US$1,790 million to US$1,820 million. Management’s decision to increase full-year revenue guidance while first-quarter earnings per share were slightly lower than a year earlier highlights confidence in cost control and...

Crown Castle (CCI) has been back in focus after fourth quarter 2025 results topped analyst estimates, followed by 2026 guidance and plans to sell its small cell and fiber businesses later this year. See our latest analysis for Crown Castle. The recent earnings beat, new 2026 guidance and the plan to sell the small cell and fiber businesses have coincided with an 11.81% 1-month share price return from Crown Castle, even though the 1-year total shareholder return of a 2.70% decline and 5-year...

Primerica stock reaction and recent performance snapshot Primerica (PRI) shares recently closed at US$257.31. The stock has seen mixed returns, with a 2.6% decline over the past day, a 6.7% decline over the past month, and a modest gain over the past 3 months. See our latest analysis for Primerica. While the 1-day share price return of 2.6% and 30-day share price return of 6.7% declines point to fading short term momentum, the 3-year total shareholder return of 59.38% and 5-year total...

In recent days, AGCO Corporation appointed former Corteva Agriscience CEO James C. Collins, Jr. to its Board of Directors, while also updating its annual incentive plan and highlighting significant expected 2026 tariff costs of about US$105 million to US$110 million at a major investor conference. This combination of governance changes, technology-focused initiatives, and tariff-related headwinds gives investors fresh information on how AGCO is balancing growth ambitions with cost and risk...

Humana (HUM) is in focus after pricing a US$1 billion junior subordinated notes offering due 2056. The notes received a stable credit rating from AM Best, drawing attention to the stock’s capital structure. See our latest analysis for Humana. Despite fresh headlines around the junior subordinated notes and new value based cardiac care partnerships, Humana’s 30 day share price return of 7.63% and year to date share price return of 32.26% highlight ongoing pressure. This is also reflected in a...

Earlier this month, Crossmint announced it is partnering with Western Union to support the rollout of USDPT, a U.S. dollar-denominated stablecoin issued on Solana, and to integrate with Western Union’s new Digital Asset Network that connects digital dollars to cash access at more than 360,000 collection points worldwide. This move is distinctive because it links on-chain stablecoin transfers directly to Western Union’s global cash payout infrastructure, potentially making digital dollars far...

In March 2026, Takeda and Protagonist Therapeutics announced that the FDA had accepted and granted Priority Review to their New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for adults with polycythemia vera, with a PDUFA target action date in the third quarter of this year. This filing, backed by Phase 3 VERIFY and long-term Phase 2 REVIVE and THRIVE data and multiple expedited regulatory designations, positions rusfertide as a potential new option for improving...

In early March 2026, Mobix Labs, Inc. reported new production purchase orders for its high-reliability electromagnetic interference protection components used in Gulfstream business jets and the U.S. Navy’s Tomahawk cruise missile program, alongside a change to its bylaws reducing the shareholder meeting quorum requirement to one-third of voting power. The fresh aerospace and defense orders underline Mobix Labs’ role as an already-qualified supplier embedded in mission-critical platforms...

Before we get into the numbers, if you are wondering whether Booking Holdings is priced attractively today, this article will walk through what the current market price might be implying about its value. Over the very short term the stock has been mixed, with a 7.3% return over the last 7 days and 2.1% over the last 30 days, while year to date the share price shows a 14.5% decline and a 1.9% decline over the last year. This is set against longer term returns of 86.9% over 3 years and 93.1%...

What Mercury General’s Recent Performance Tells You Mercury General (MCY) has attracted fresh attention after a strong 1 year total return of 71.35%, alongside mixed shorter term moves, including a month decline of about 4.95% and a modest gain over the past 3 months. See our latest analysis for Mercury General. The recent pullback, including a 1 month share price return of about a 5% decline from a last close of US$90.48, sits against a much stronger 1 year total shareholder return of...

NIQ Global Intelligence: Recent Price Moves and Business Snapshot NIQ Global Intelligence (NIQ) has drawn fresh attention after recent share price swings, with the stock down 2.5% over the past day, weaker over the past week, but positive over the past month. For investors looking at the consumer data and analytics space, NIQ sits in an interesting position. The company reports annual revenue of US$4,198.4m and a net loss of US$353.3m, while its value score stands at 6. Over the past 3...

RXO (RXO) stock has been under pressure after reports of rising transportation costs and large share reductions by some institutional holders, which have sharpened investor focus on margin resilience and balance sheet strength. See our latest analysis for RXO. RXO’s recent selloff, including a 1 day share price return of 11.07% decline and a 7 day share price return of 13.91% decline to US$13.74, comes after months of softer results. The 1 year total shareholder return of 30.64% decline shows...

The weak February U.S. jobs report, which showed a loss of 92,000 jobs and unemployment at 4.4%, triggered a 3.6% drop in Enova International (ENVA), highlighting investor concern around credit conditions and demand. See our latest analysis for Enova International. That jobs-driven drop comes after a tougher few weeks for the share price, with a 30 day share price return of a 14.6% decline and a year to date share price return of a 15.05% decline, even though the 1 year total shareholder...

Cabot (CBT) is back in focus after first quarter fiscal 2026 results that beat earnings estimates, but came with lower year over year sales and a trimmed adjusted EPS outlook. See our latest analysis for Cabot. The earnings beat has not stopped selling pressure in the short term, with a 1 day share price return of 5.40% decline and a 7 day share price return of 8.04% decline. At the same time, the 90 day share price return of 8.49% and 5 year total shareholder return of 46.88% point to a...

Septerna, Inc. recently reported positive Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing favorable tolerability, once-daily pharmacokinetics and clinical proof-of-mechanism in humans. The company’s decision to move SEP-631 into a Phase 2b trial for chronic spontaneous urticaria, alongside an open-label study in chronic inducible urticaria, highlights a focused push into difficult-to-treat allergic skin conditions. We will now examine how SEP-631’s...

Wingstop stock snapshot after recent performance Wingstop (WING) has been on many watchlists after a recent stretch of weaker returns, including a 3% decline in the latest session and double digit pullbacks over the past month and past 3 months. See our latest analysis for Wingstop. That 3% one day share price drop at around $229.17 caps a weaker run, with 7 day and 30 day share price returns of 11.69% and 13.20% declines, while the 5 year total shareholder return of 88.85% shows a very...